Overview

GIPSE is a network of health economists dedicated to achieving the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, GIPSE seeks to enhance clinical outcomes, increase efficiency of service delivery, and increase access to these promising therapies for everyone who can benefit. Here is a partial list of current projects:

• In collaboration with the Usona Institute, modeling the cost-effectiveness of psilocybin-assisted psychotherapy to treat major depressive disorders.

• In collaboration with the Multidisciplinary Association for Psychedelic Studies (MAPS), evaluating the cost-effectiveness of MDMA-assisted therapy for people with chronic PTSD.

• In collaboration with Johns Hopkins University’s Center for Psychedelic and Consciousness Research, evaluating the cost-effectiveness of psilocybin-assisted therapy for smoking cessation.

• Modeling the short and long-term epidemiological, economic, and budgetary impacts of scaled-up access to psychedelic therapies at the state and national level.

This two-page summary provides additional information on GIPSE’s mission and activities. 

Publications

Here is a link to publications from the GIPSE team on the economics of psychedelic therapies:

• The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD (plos.org)
• Updated cost-effectiveness of MDMA-assisted therapy for the treatment of post traumatic stress disorder in the United States: Findings from a phase 3 trial (semanticscholar.org)
• The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study (springer.com)
• The economics of psychedelic-assisted therapies: A research agenda (Frontiersin.org)

GIPSE Conferences and Press

Here is a link to GIPSE's latest news, including upcoming/past conferences, presentations, interviews, and print.

GIPSE in the News

• Psychedelic Alpha interviewed Elliot Marseille in November 2022. Access it here.

• (7-Dec-22) Green Market Report: Medical Insurance Providers Assess Benefits of Psychedelics Treatments (greenmarketreport.com)

• (7-Dec-22) Psychedelic therapy moving to next frontier: workplace perk - STAT (statnews.com)

• (14-Nov-22) Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics (GIPSE) - Psychedelic Alpha

• (17-Oct-22) Will Medical Insurers Agree to Cover Psychedelic Trips? - Bloomberg

Advisory Council

• Rick Doblin, Executive Director, Multidisciplinary Association for Psychedelic Studies (MAPS)

• Matthew Johnson, Associate Center Director, Johns Hopkins University, Center for Psychedelics & Consciousness Research

• Tura Patterson, Senior Director, Strategic partnerships, Usona Institute

• Eduardo Schenberg, Founder, Instituto Phaneros (São Paolo, Brazil)